Saving Stroke Patients around the world
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
Szukaj
Our Commitment
We want to create value in areas of unmet medical need and engage with communities and society to improve lives – for humans and animals.
Antibody therapeutics business partnering PetMedix
Combining PetMedix’ expertise in veterinary biotherapeutic technology with Boehringer Ingelheim’s long experience and innovation in human antibody discovery and development provides a unique opportunity for the partners.
Performance Indicators
Performance indicators concerning Environment Health and Safety (EHS) are summarized here.
Supply Chain Scholarship for Cowtribe
A supply chain course we sponsored boosted the career of Latifa Saaka
Lead with Pride – for the Benefit of All.
How Inclusive Leadership advocates for Acceptance and creating a Sense of Belonging
BI Access to Healthcare Strategy_Availability
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Our Innovation Strategy
Our discovery research strategy is designed to sustain our track record of innovation and look for new and breakthrough medicines.
Our Partners Harvard
Brock Reeve, Executive Director of the Harvard Stem Cell Institute, talks about the importance of working together to tackle the challenge of fibrosis.
Advancing regenerative medicine
Strategic partnerships play a key role in helping the company accelerate the next generation of breakthroughs.
Patient Safety
Patient Safety
About Boehringer Ingelheim Partnering Days
Find out more about our partnering days and how we can work together to accelerate your science
View from Both Sides of the Table
Stawiamy na zarządzanie aliansami
Our-position
Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
Supporting grooms in equestrian sports
Find out how one organization can change the lives of those who dedicate their careers to horse care.
Heart murmur in dogs: symptoms and how to treat it
Monitoring your dog’s heart can save its life
Behind the Lab
Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
Historia Boehringer Ingelheim w latach 1948-1990,
Historia Boehringer Ingelheim w latach 1948-1990, z kamieniami milowymi
Europe needs a vibrant research eco-system
At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.
One step further in fighting rabies in Vietnam
A expedition team set off to the Duc Hue District. The purpose? To vaccinate the entire dog and cat population of several villages.
Historia (1885-1948): Nowatorskie początki
Historia Boehringer Ingelheim od rozpoczęcia działalności w 1885 roku do 1948 roku, z kamieniami milowymi i ważnymi produktami
Women in STEM 2022
Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.
Championing novel science
Dr. Vikas Mohan Sharma announces FDA fast-track designation for BI 1358894 as potential treatment for Borderline Personality Disorder.